Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04624555 · ClinicalTrials.gov registry record

The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors

A clinical trial of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT04624555 is a study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 907-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04624555, a study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to determine whether testing of stool for a panel of markers will enable us to detect polyps and cancer compared to standard testing.

Study Locations (1)

Ohio

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-10-31
Est. Completion 2026-01-30

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT04624555

The ClinicalTrials.gov registry entry for NCT04624555 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 907-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (94% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 0 interventions.

NCT04624555 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04624555 about?

NCT04624555 is a clinical study titled "The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors". The purpose of this research study is to determine whether testing of stool for a panel of markers will enable us to detect polyps and cancer compared to standard testing.

What is the current status of trial NCT04624555?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-10-31. Estimated completion is 2026-01-30.

What conditions does trial NCT04624555 study?

This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Adenocarcinoma of the Colon, Stage III Colorectal Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer.

Who is sponsoring clinical trial NCT04624555?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04624555 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adenocarcinoma of the Rectum

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.